TaiMed Biologics

中裕新藥股份有限公司 · 4147

What it does

Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.

TaiMed Biologics develops and commercializes CD4-targeted biologics and differentiated antibody therapies for long-acting HIV treatment.^[1]

The company's commercial product Trogarzo is an anti-HIV monoclonal antibody drug used to provide long-acting treatment for AIDS patients with multiple drug resistance.^[2]

Its lead clinical program is the TMB-365/380 combination, a long-acting dual-antibody maintenance regimen targeting HIV maintenance therapy.^[2]

Additionally, the company provides CDMO services including process development, analytical development, formulation, cGMP manufacturing, and regulatory support.^[1]

Monthly revenue

Latest month	Revenue	Year on year	Month on month
2026-10	NT$52m	+35.7%	-2.7%

2024-11 to 2026-10, monthly revenue.

Foreign investors

Last 20 trading days	Net
2026-10-12 to 2026-11-10	+NT$97m

Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.

Facts

Full English name	TaiMed Biologics Inc.
Chinese name	中裕新藥股份有限公司
Stock code	4147 (TPEx)
Industry	Biotech & medical
Founded	05 Sep 2007
Listed	23 Nov 2015
Paid-in capital	NT$2.7bn
Chairman	陳明村
President	張金明
Headquarters	3F., No.607, Ruiguang Rd., Neihu Dist Taipei City, 11492 Taiwan. R.O.C.
Website	https://www.taimedbiologics.com
Official business description	新藥研發

Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.

Sources

Taimed Biologics · website · retrieved 04 Nov 2026
Annual report 2025 (English), business scope · annual_report · retrieved 04 Nov 2026

The Week in Taiwan Companies · free, every Friday
Using it at work? Join the team-plan waiting list